|
gptkbp:instanceOf
|
gptkb:drug
mineralocorticoid receptor antagonist
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
C03DA04
|
|
gptkbp:brand
|
Inspra
|
|
gptkbp:CASNumber
|
107724-20-9
|
|
gptkbp:contraindication
|
severe renal impairment
hyperkalemia
concomitant use with strong CYP3A4 inhibitors
|
|
gptkbp:discoveredBy
|
gptkb:Pharmacia
|
|
gptkbp:eliminationHalfLife
|
4-6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:has_stereochemistry
|
yes
|
|
gptkbp:hasMolecularFormula
|
C24H30O6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
eplerenone
|
|
gptkbp:KEGGID
|
D07913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks aldosterone at mineralocorticoid receptor
|
|
gptkbp:meltingPoint
|
248-250°C
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:partOf
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
50%
|
|
gptkbp:PubChem_CID
|
391697
443872
CHEMBL1201357
DB00700
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
hyperkalemia
increased creatinine
|
|
gptkbp:synonym
|
SC-66110
|
|
gptkbp:UNII
|
Q10VZK4B6U
|
|
gptkbp:usedFor
|
heart failure
hypertension
|
|
gptkbp:bfsParent
|
gptkb:aldosterone_antagonists
gptkb:primary_aldosteronism
|
|
gptkbp:bfsLayer
|
7
|